Inovio Pharmaceuticals
Biotechnology company developing DNA medicines that use in vivo protein expression to target HPV-related diseases, cancer and infectious diseases. Operates activities across discovery, translational research, clinical development, manufacturing and regulatory strategy with a stated focus on advancing a lead DNA medicine candidate toward potential approval.
Industries
Nr. of Employees
medium (51-250)
Inovio Pharmaceuticals
Patents
Products
DNA medicines platform
Platform technologies to design DNA-based therapeutics that induce in vivo expression of target proteins for therapeutic or prophylactic use.
Lead DNA-medicine candidate for recurrent respiratory papillomatosis (RRP)
A lead clinical-stage DNA-medicine candidate being advanced toward potential regulatory approval for treatment of recurrent respiratory papillomatosis.
DNA-encoded
Core DNA medicines platform encoding the DNA sequence for a specific monoclonal antibody in a DNA plasmid for in vivo manufacturing.
DNA-encoded protein technology
Therapeutic protein replacement approach targeting long-term protein expression via DNA plasmids.
CELLECTRA
Proprietary investigational smart delivery devices designed to deliver DNA medicines into the body's cells for optimal effect without chemical adjuvants, lipid nanoparticles, or viral vectors.
DNA-launched Nanoparticles
Platform combining high immunogenicity benefits of nanoparticle-based vaccines with the in vivo protein production abilities of DNA medicines.
DNA medicines platform
Platform technologies to design DNA-based therapeutics that induce in vivo expression of target proteins for therapeutic or prophylactic use.
Lead DNA-medicine candidate for recurrent respiratory papillomatosis (RRP)
A lead clinical-stage DNA-medicine candidate being advanced toward potential regulatory approval for treatment of recurrent respiratory papillomatosis.
DNA-encoded
Core DNA medicines platform encoding the DNA sequence for a specific monoclonal antibody in a DNA plasmid for in vivo manufacturing.
DNA-encoded protein technology
Therapeutic protein replacement approach targeting long-term protein expression via DNA plasmids.
CELLECTRA
Proprietary investigational smart delivery devices designed to deliver DNA medicines into the body's cells for optimal effect without chemical adjuvants, lipid nanoparticles, or viral vectors.
DNA-launched Nanoparticles
Platform combining high immunogenicity benefits of nanoparticle-based vaccines with the in vivo protein production abilities of DNA medicines.
Expertise Areas
- DNA medicine research and development
- Clinical trial management for biologics and DNA therapeutics
- Biological manufacturing and cGMP clinical supply
- Regulatory strategy and global agency engagement
Key Technologies
- DNA medicines / DNA vaccines
- Plasmid DNA production
- In vivo protein expression
- Immuno-oncology therapeutics
News & Updates
Company announcement regarding a favorable judgment in litigation.
Announcement of intended participation in investor conferences.
Quarterly financial results and business update for Q2 2026.
Company announcement regarding a favorable judgment in litigation.
Announcement of intended participation in investor conferences.
Quarterly financial results and business update for Q2 2026.